Literature DB >> 20093263

Effects of a simple intraoperative intrathoracic hyperthermotherapy for lung cancer with malignant pleural effusion or dissemination.

Michitaka Kimura1, Takashi Tojo, Hiroshi Naito, Yoko Nagata, Norikazu Kawai, Shigeki Taniguchi.   

Abstract

We examined the effect of a simple intraoperative intrathoracic hyperthermotherapy (IIH) and a simple intraoperative intrathoracic hyperthermo-chemotherapy (IIHC) on malignant pleural effusion and/or dissemination with primary non-small lung cancer. This study included 19 patients who had malignant pleural effusion and/or dissemination recognized for the first time at the time of surgery. We performed surgical procedures on the primary lesions and then the additional therapies followed. Seven patients received IIH (group A), five patients underwent IIHC (group B), and seven patients did not have any additional therapy (group C). There was no death during the follow-up period (9-35 months) in the group A. The median survival time was 41 months in the group B and 25 months in the group C. The group A was completely free of pleural effusion and one patient in the group B suffered from pleural effusion 26 months after surgery, although the median term of freedom from pleural effusion was three months in the group C. In patients with malignant pleural effusion and/or dissemination with primary non-small lung cancer, not only IIHC but also IIH might be beneficial in the prevention of pleural effusion instead of the improvement in prognosis.

Entities:  

Mesh:

Year:  2010        PMID: 20093263     DOI: 10.1510/icvts.2009.225110

Source DB:  PubMed          Journal:  Interact Cardiovasc Thorac Surg        ISSN: 1569-9285


  9 in total

1.  Prospective validation of quantitative NSE mRNA in pleural fluid of non-small cell lung cancer patients.

Authors:  Dongfang Tang; Mingzhao Wang; Aihua Sui; Yongjie Wang; Ronghua Yang; Zizong Wang; Yandong Zhao; Wenjie Jiao; Yi Shen
Journal:  Med Oncol       Date:  2013-09-01       Impact factor: 3.064

Review 2.  In lung cancer patients where a malignant pleural effusion is found at operation could resection ever still be justified?

Authors:  Alfonso Fiorelli; Mario Santini
Journal:  Interact Cardiovasc Thorac Surg       Date:  2013-05-08

Review 3.  The Role of Thoracic Surgery in the Therapeutic Management of Metastatic Non-Small Cell Lung Cancer.

Authors:  Elizabeth A David; James M Clark; David T Cooke; Joy Melnikow; Karen Kelly; Robert J Canter
Journal:  J Thorac Oncol       Date:  2017-08-24       Impact factor: 15.609

4.  Debulking surgery and hyperthermic intrathoracic chemotherapy (HITHOC) for lung cancer.

Authors:  Marcello Migliore
Journal:  Chin J Cancer Res       Date:  2017-12       Impact factor: 5.087

5.  Clinical outcomes of cytoreductive surgery combined with intrapleural perfusion of hyperthermic chemotherapy in advanced lung adenocarcinoma with pleural dissemination.

Authors:  Eunjue Yi; Daejoong Kim; Sukki Cho; Kwhanmien Kim; Sanghoon Jheon
Journal:  J Thorac Dis       Date:  2016-07       Impact factor: 2.895

Review 6.  Narrative review of theoretical considerations regarding HITHOC between past and future.

Authors:  Tamas F Molnar; Andras Drozgyik
Journal:  Ann Transl Med       Date:  2021-06

Review 7.  A narrative review of hyperthermic intrathoracic chemotherapy for advanced lung cancer.

Authors:  Kimberly Song; Raja M Flores
Journal:  Ann Transl Med       Date:  2021-06

Review 8.  New horizons in non-small-cell lung cancer patients with ipsilateral pleural dissemination (M1a): review of the literature.

Authors:  Hao Li; Taorui Liu; Zewen Sun; Zhenfan Wang; Xianping Liu; Fan Yang
Journal:  Ann Transl Med       Date:  2021-06

9.  The prognostic analysis of lung cancer patients with occult malignant pleural disease at thoracotomy.

Authors:  Shaolei Li; Xin Yang; Shanyuan Zhang; Miao Huang; Yuanyuan Ma; Yue Yang
Journal:  Transl Cancer Res       Date:  2020-03       Impact factor: 1.241

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.